Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06639724 · ClinicalTrials.gov registry record · Phase 1
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
A Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06639724: Recruiting Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by University of California, San Diego.
NCT06639724 is a Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC) that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 36 participants, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06639724, a Phase 1 study of Pancreatic Ductal Adenocarcinoma (PDAC), is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non metastatic pancreatic ductal adenocarcinoma (PDAC).
Primary Outcome
Number and percentage of participants who experience surgical delay, as measured by the proportion of enrolled participants for whom pancreatic resection cannot be performed within 6 weeks of the last pre-operative treatment cycle.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
Study Locations (1)
California
- University of California, San Diego Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06639724 shows while recruiting
NCT06639724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (PDAC) appearing as the primary indexed condition, and to 1 intervention - of which Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) is the first listed.
NCT06639724 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06639724 about?
NCT06639724 is a clinical study titled "Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer". This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non me...
What is the current status of trial NCT06639724?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-12-05. Estimated completion is 2028-12.
What conditions does trial NCT06639724 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (PDAC).
What interventions are being tested in trial NCT06639724?
The interventions under investigation include: Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06639724?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06639724 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma (PDAC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06639724's enrollment target sits among peer trials
36 15th of 16 higher than 2 of 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma (PDAC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI